Becton, Dickinson and Company
BD Enters Third Amended Credit Agreement
Summary
On September 16, 2025, Becton, Dickinson and Company entered into a third amended and restated credit agreement with Citibank, N.A. as administrative agent, providing the Company with a $2.75 billion revolving credit facility, including a $100 million letter of credit subfacility and a $236 million swingline loan subfacility. The agreement expires in September 2030, with an option to extend for up to two additional years. The facility includes financial covenants and customary events of default.
Profitelligence Alerts
Get alerts for BDX
Be first to know when Becton, Dickinson and Company files with the SEC.
Filing Categories
Advertisement
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.
Official SEC Documents
Advertisement